(Total Views: 96)
Posted On: 03/28/2025 6:00:58 PM
Post# of 110
NetworkNewsBreaks – Zacks Maintains $35.00 Price Per Share Valuation for Soligenix Inc. (NASDAQ: SNGX) Amid Promising Vaccine and CTCL Therapy Progress
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, was spotlighted in a recent Zacks Small-Cap Research report that presented a favorable analysis, emphasizing the company’s advancements in vaccine and photodynamic therapy technologies.
The study highlights promising preclinical data for CiVax(TM), a thermostabilized COVID-19 booster, which demonstrated broad immune protection in non-human primates. Zacks also notes the continued progress of HyBryte(TM), Soligenix’s lead candidate for cutaneous T-cell lymphoma (“CTCL”), now in a second confirmatory Phase 3 trial, following successful results in its first Phase 3 study. Based on its discounted cash flow model that takes into account potential future revenues from HyBryte(TM), SGX302 (mild-to-moderate psoriasis), and SGX945 (Behcet’s Disease), the firm maintains a valuation of $35.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, was spotlighted in a recent Zacks Small-Cap Research report that presented a favorable analysis, emphasizing the company’s advancements in vaccine and photodynamic therapy technologies.
The study highlights promising preclinical data for CiVax(TM), a thermostabilized COVID-19 booster, which demonstrated broad immune protection in non-human primates. Zacks also notes the continued progress of HyBryte(TM), Soligenix’s lead candidate for cutaneous T-cell lymphoma (“CTCL”), now in a second confirmatory Phase 3 trial, following successful results in its first Phase 3 study. Based on its discounted cash flow model that takes into account potential future revenues from HyBryte(TM), SGX302 (mild-to-moderate psoriasis), and SGX945 (Behcet’s Disease), the firm maintains a valuation of $35.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
